China explores new mode of pharmaceutical R&D

May 3, 2021 | Monday | News

Link Health and George Clinical to establish an independent joint venture clinical development company

Image credit- shutterstock.com

Image credit- shutterstock.com

Guangzhou Link Health Pharma Co., Ltd. (Link Health), based in China, and Australian firm George Clinical Pty Ltd (George Clinical) have signed a term sheet to enter into a strategic agreement to establish an independent joint venture clinical development company called Link-George Clinical Research Co., Ltd (Link-George).

Link-George will deliver clinical trials for Link Health and related companies that it has entered into licensing deals with. The plan is for Link-George to launch six clinical trials in 2021 and this is expected to grow as Link Health’s in-licensed portfolio expands.

Link-George will be majority owned by Link Health and operationally led by George Clinical with a board that comprises representatives from both Link Health and George Clinical.

George Clinical is a leading Asia Pacific contract research organization with more than 20 years of experience and a global reach across 38 countries. Collaborating with clients in the areas of biopharmaceuticals, medical devices and diagnostics, it provides a full range of clinical trial services related to all trial phases, registration and post-marketing trials. 

Sign up for the editor pick and get articles like this delivered right to your inbox.

+Country Code-Phone Number(xxx-xxxxxxx)

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

Survey Box

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls